Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 108

Results For "CE"

11056 News Found

Alembic announces USFDA final approval for Dasatinib Tablets
Drug Approval | November 08, 2025

Alembic announces USFDA final approval for Dasatinib Tablets

The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets


Alembic receives FDA final approval for Sumatriptan Injection USP
Drug Approval | November 08, 2025

Alembic receives FDA final approval for Sumatriptan Injection USP

Sumatriptan injection is indicated in adults for the acute treatment of migraine


Lupin Bioresearch Center receives zero observations from USFDA
Drug Approval | November 08, 2025

Lupin Bioresearch Center receives zero observations from USFDA

A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations


Lilly, Novo Nordisk closer to deal with Trump administration to slash obesity drug prices to $149/month
News | November 07, 2025

Lilly, Novo Nordisk closer to deal with Trump administration to slash obesity drug prices to $149/month

The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies


Philips reiterates FY25 outlook following steady Q3 performance
News | November 07, 2025

Philips reiterates FY25 outlook following steady Q3 performance

Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year


Sovato secures series B funding to advance remote robotic surgery platform
Medical Device | November 07, 2025

Sovato secures series B funding to advance remote robotic surgery platform

The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies


Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3
News | November 07, 2025

Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3

Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion


EazeBio and UC Santa Cruz partner to advance instrument-free diagnostic platform
News | November 06, 2025

EazeBio and UC Santa Cruz partner to advance instrument-free diagnostic platform

Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible


RedHill secures final $10.5M court judgment for enforcement
Biopharma | November 06, 2025

RedHill secures final $10.5M court judgment for enforcement

RedHill has obtained a court-approved asset attachment in South Korea to prevent Kukbo from transferring or disposing of assets ahead of enforcement of the judgment